U
UTHR icon

UBS’s United Therapeutics UTHR Stock Holding History

UBS’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-600
Closed -$68K – 10835
2013
Q4 		$68K Buy
600
+300
+100% +$27.1K ﹤0.01% 6557
2013
Q3 		$24K Sell
300
-1,500
-83% -$110K ﹤0.01% 7831
2013
Q2 		$118K Buy
+1,800
New +$116K ﹤0.01% 5707

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS's UTHR Position: Q3 2014 in Review

UBS reduced its United Therapeutics (UTHR) stake by 6.7% in Q3 2014, selling an estimated $228K and leaving 30,831 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2258.

UBS first reported a position in UTHR in Q2 2013 and has held it in 6 quarters since. The position peaked at $5.6M in Q4 2013. 319 funds tracked by Wall St. Rank hold UTHR as of Q3 2014.

  • UBS held 30,831 shares of United Therapeutics worth $3.97M as of Q3 2014.
  • UBS sold 2,208 United Therapeutics shares in Q3 2014, an estimated $228K.
  • United Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2258 holding.
  • UBS first reported a position in United Therapeutics in Q2 2013 and has held it in 6 quarters since.
  • UBS's United Therapeutics position peaked at $5.6M in Q4 2013.
  • 319 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.